ABN/ARSN

Rule 3.8A

## Appendix 3E

## Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity

	ma Pharmaceuticals Limited		15 088 417 403
We	(the entity) give ASX the following	information.	
Inf	formation about buy-back		
1	Type of buy-back	On-market buy-back	
2	Date Appendix 3C was given to ASX	13 September 2012	
	tal of all shares/units bought ve been received, before, and	*	o which acceptances  Previous day
		1	
			_
3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	62,419,101	172,001
3	back or if buy-back is an equal access scheme, in relation to which	62,419,101 \$44,810,713	\$98,109
	back or if buy-back is an equal access scheme, in relation to which acceptances have been received  Total consideration paid or		

		Before p	revious	s day	Previous day
5	If buy-back is an on-market buy-back	Highest \$0.8525	price	paid:	Highest price paid: \$0.5750
		Lowest	n=inn	noide	Lowest price paid: \$0.5675
		\$0.5600	price	paid:	Highest price allowed under rule 7.33: \$0.6017

## How many shares/units may still be bought back?

6	If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back	56,039,250
	maximum number of shares/units – the remaining number of	

## **Compliance statement**

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

(Director/Company secretary)

Sign here:

Print name: SUE MORGAN

Date: 1 November 2013